Published in Adv Exp Med Biol on January 01, 1998
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol (2004) 2.47
A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol (2002) 2.02
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother (2002) 1.27
Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol (2009) 1.07
DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother (2001) 0.75
Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science (1995) 11.38
Human ICE/CED-3 protease nomenclature. Cell (1996) 7.11
Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science (1997) 5.16
Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol (1997) 3.56
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis (1995) 2.42
Response to local inflammation of IL-1 beta-converting enzyme- deficient mice. J Immunol (1997) 2.10
Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes. Proc Natl Acad Sci U S A (1992) 1.82
Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1beta-converting enzyme (caspase-1)-deficient mice. Blood (1998) 1.63
Interleukin-1 beta converting enzyme requires oligomerization for activity of processed forms in vivo. EMBO J (1995) 1.60
Cleavage of poly(ADP-ribose) polymerase by interleukin-1 beta converting enzyme and its homologs TX and Nedd-2. J Biol Chem (1995) 1.48
PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. J Biol Chem (1992) 1.38
Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J Biol Chem (1996) 1.34
FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. J Biol Chem (1997) 1.32
Myoglobin diffusion in bovine heart muscle. Science (1983) 1.29
8-Hydroxy-5-deazaflavin-reducing hydrogenase from Methanobacterium thermoautotrophicum: 1. Purification and characterization. Biochemistry (1987) 1.25
Substrate and inhibitor specificity of interleukin-1 beta-converting enzyme and related caspases. J Biol Chem (1997) 1.24
Enthalpy of hydrogen bond formation in a protein-ligand binding reaction. Proc Natl Acad Sci U S A (1994) 1.21
Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. J Biol Chem (1992) 1.18
Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine (1996) 1.17
Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Biochemistry (1997) 1.09
FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. Protein Eng (1996) 1.06
Sphingomyelinase activity at pH 7.4 in human brain and a comparison to activity at pH 5.0. J Lipid Res (1976) 1.05
Overexpression of p59-HBI (FKBP59), full length and domains, and characterization of PPlase activity. Biochem Biophys Res Commun (1993) 1.05
FK506 binding protein mutational analysis. Defining the surface residue contributions to stability of the calcineurin co-complex. J Biol Chem (1995) 1.04
Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallogr D Biol Crystallogr (1995) 1.00
Proton NMR study of yellowfin tuna myoglobin in whole muscle and solution. Evidence for functional metastable protein forms involving heme orientational disorder. J Biol Chem (1985) 0.98
Myoglobin: cytochrome b5 interactions and the kinetic mechanism of metmyoglobin reductase. J Biol Chem (1985) 0.94
The in vitro antimicrobial efficiency of essential oils. Indian J Med Res (1970) 0.92
Immunosuppressive activity of [MeBm2t]1-, D-diaminobutyryl-8-, and D-diaminopropyl-8-cyclosporin analogues correlates with inhibition of calcineurin phosphatase activity. J Immunol (1993) 0.90
Identification of 7alpha-, 12alpha-dihydroxy-3-oxo cholanoic acid as the major degradation product from cholic by C. perfringens. J Steroid Biochem (1978) 0.87
Niemann-Pick disease type D: lipid analyses and studies on sphingomyelinases. Ann Neurol (1977) 0.82
Design and synthesis of novel conformationally restricted HIV protease inhibitors. Bioorg Med Chem Lett (1998) 0.81
Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis. Biochemistry (1996) 0.78
Structure-function analysis of tissue-type plasminogen activator by linker-insertion, point and deletion mutagenesis. Protein Eng (1989) 0.77
Opiate peptide receptors on intact NIE-115 neuroblastoma: radioligand binding properties, intracellular response, and effects of increasing membrane cholesterol. Prog Neuropsychopharmacol Biol Psychiatry (1984) 0.77
Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors. Bioorg Med Chem Lett (1998) 0.77
Effects of membrane polyunsaturated fatty acids on opiate peptide inhibition of basal and prostaglandin E1-stimulated cyclic AMP formation in intact N1E-115 neuroblastoma cells. Biochem Pharmacol (1987) 0.75
Tissue-type plasminogen activator variants with domain duplications and rearrangements. Protein Eng (1989) 0.75
Practical applications of time-averaged restrained molecular dynamics to ligand-receptor systems: FK506 bound to the Q50R,A95H,K98I triple mutant of FKBP-13. J Biomol NMR (1996) 0.75
Muscarinic cholinergic receptors in the embryonic chick heart: interaction of agonist, receptor, and guanine nucleotides studied by an improved assay for direct binding of the muscarinic agonist [3H]cismethyldioxolane. Mol Pharmacol (1987) 0.75
Pharmacokinetics in chimpanzees of recombinant human tissue-type plasminogen activator produced in mouse C127 and Chinese hamster ovary cells. Chem Pharm Bull (Tokyo) (1990) 0.75
Formation of ether-soluble Griess reagent-positive material from human feces and sodium nitrite. Environ Res (1980) 0.75
Myoglobin interspecies structural differences: effects on autoxidation and oxygenation. Arch Biochem Biophys (1986) 0.75
Anti-inflammatory activity of the leaves and bark of delonix elata. Anc Sci Life (1997) 0.75
Isolation and characterization of metmyoglobin reductase from yellowfin tuna (Thunnus albacares). Comp Biochem Physiol B (1985) 0.75
Automation of a high-performance liquid chromatography-based enzyme assay: evaluation of inhibition constants for human immunodeficiency virus-1 protease inhibitors. Anal Biochem (1995) 0.75
An oxidimetric method for the determination of thiophanatemethyl in commercial formulations. Talanta (1988) 0.75
Nitrite-induced volatile fecal mutagens: some preliminary studies. Cancer (1982) 0.75
A microcomputer-based high-speed data-acquisition system for a stopped-flow spectrophotometer: PDP-11 architecture interfaced to a commercial instrument. J Automat Chem (1983) 0.75
Suitability of groundnut peptone for general bacteriological work. Indian J Pathol Bacteriol (1968) 0.75
Colorimetric method for the determination of captafol (difolatan) in commercial formulations and residues on grains and apples. Analyst (1991) 0.75
Solution structure of FK506 bound to the R42K, H87V double mutant of FKBP-12. Biochemistry (1994) 0.75
Cytogenetic studies on the F1 hybrid Solanum indicum x S. torvum. Theor Appl Genet (1981) 0.75
Studies on the crossability relationships of some spinous Solanums. Theor Appl Genet (1984) 0.75
Nitrite-induced volatile mutagens from normal human feces. Cancer (1981) 0.75
Model systems demonstrating the volatile mutagenicity and carcinogenicity of sodium nitrite in rats. Experientia (1984) 0.75